Company Name Catabasis Pharmaceuticals
Mailing Address One Kendall Square Bldg. 1400E Cambridge, MA 02139
Company Description At Catabasis we are dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. We have assembled a team of highly motivated and experienced scientists who are committed to improving the lives of patients.
Proceeds Purposes Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline.